Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study

References

• National Osteoporosis Foundation. Disease facts [online]. Available from http://www.nof.org/osteoporosis/diseasefacts.htm/ [last accessed 22 February 2007]
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al.; for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. J Am Med Assoc 1999;282: 1344–52
   Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al.; on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
   Google Scholar
• McClung MR, Geusens P, Miller PD, et al.; for the Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 2001;344:333–40
   Google Scholar
• Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103–11 [Epub 2002 June 27]
   Google Scholar
• Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686–94
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006;12:522–8
   Google Scholar
• Raisz L, Smith JA, Trahiotis M, et al. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporosis Int 2000;11:615–20
   PubMed Web of Science ®Google Scholar
• FDA CDER. Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Issued 4/1994 [online]. Available from http://www.fda.gov/cder/guidance/osteo.pdf/ [last accessed 22 February 2007]
   Google Scholar
• Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051–6
   PubMed Web of Science ®Google Scholar
• Delmas PD, Eastell R, Garnero P, et al.; for the Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 2000;11(Suppl 6):S2–S17
   Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433–9
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129–35 [Epub 2003 December 5]
   Google Scholar
• Burgio DE, Russell DA, Desliva B, et al. Risedronate pharmacokinetics following daily (5 mg/day) and weekly (35 and 50 mg/week) oral dosing regimens to postmenopausal women. Clin Pharmacol Ther 2002;71:32 [Abstract ID357]
   Google Scholar
• Mitchell DY, Eusebio RA, Sacco-Gibson NA, et al. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers. J Clin Pharmacol 2000;40:258–65
   Google Scholar
• Singer FR, Clemens TL, Eusebio RA, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget’s disease. J Clin Endocrinol Metab 1998;83: 1906–10
   PubMed Web of Science ®Google Scholar
• Hosking DJ, Eusebio RA, Chines AA. Paget’s disease of bone: reduction of disease activity with oral risedronate. Bone 1998;22:51–5
   Google Scholar
• Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone [Paget’s Risedronate/Etidronate Study Group]. Am J Med 1999;106:513–20
   PubMed Web of Science ®Google Scholar
• Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget’s disease of bone: an open label, multicenter study. J Bone Miner Res 1998;13:1032–8
   PubMed Web of Science ®Google Scholar
• Brown JP, Hosking DJ, Ste-Marie L, et al. Risedronate, a highly effective, short-term oral treatment for Paget’s disease: a dose–response study. Calcif Tissue Int 1999;64:93–9
   Google Scholar
• Delaney MF, Hurwitz S, Shaw J, LeBoff MS. Bone density changes with once weekly risedronate in postmenopausal women. J Clin Densitom 2003;6:45–50
   PubMed Web of Science ®Google Scholar